Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit,

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of treatment responses SEATTLE, Dec. 07, 2024 (GLOBE ...

Chad Robins, CEO & Co-Founder, emphasized "another quarter of strong execution and accelerating momentum across the business," highlighting meaningful wins in profitability and growth for the MRD segment. He noted, "This quarter, adjusted EBITDA was $7 ...

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) surged around 16% in premarket trading on Monday after the company reported preliminary fourth-quarter revenue that came in well ahead of analyst forecasts.

Adaptive shares are trading higher on possible continued momentum after the company announced preliminary fourth-quarter and fiscal-year revenues above estimates.

The MarketWatch News Department was not involved in the creation of this content. A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR ...

SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today ...

Adaptive Biotechnologies Corporation and Flatiron Health have announced the integration of Adaptive's clonoSEQ® test for measurable residual disease (MRD) assessment into Flatiron's OncoEMR® electronic medical record platform. This integration allows ...

The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. The commercial-stage Adaptive booked $58.9 million in revenue for the period, a robust 36% improvement ...